Therapeutics News and Research

RSS

GTHP provides update on FDA PMA review for LightTouch non-invasive cervical cancer test

Guided Therapeutics, Inc., today provided an update on the U.S. Food and Drug Administration review process for its premarket approval application for the LightTouch non-invasive test for the early detection of cervical pre-cancer.

8 Mar 2011

IRB approves Guided Therapeutics light-based Barrett's Esophagus detection technology for human trial

Guided Therapeutics, Inc., developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has received Institutional Review Board approval to begin testing its light-based detection technology in humans for Barrett's Esophagus, a precursor for esophageal cancer.

8 Mar 2011

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.

8 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

Duchenne Parent Project awards grant to AMT for DMD gene therapy

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the Duchenne Parent Project, based in the Netherlands, has awarded AMT a grant of EUR 145,000 to support the development of AMT-080, AMT's gene therapy for Duchenne Muscular Dystrophy.

7 Mar 2011

NCRM, CSCRM to become national force in regenerative medicine

In a move to streamline and accelerate the research and development of new stem cell and regenerative medicine technologies, the National Center for Regenerative Medicine and the Center for Stem Cell and Regenerative Medicine at Case Western Reserve University have been rolled into a single entity housed within the university's School of Medicine.

5 Mar 2011

CDI announces publication of footprint-free iPSCs production method in PLoS ONE journal

Cellular Dynamics International, the world's largest producer of human tissue cells for drug discovery and safety testing, today announced the publication of research demonstrating an efficient and scalable method of creating DNA integration-free, or footprint-free, induced pluripotent stem cells under a feeder-free condition using chemically defined media.

5 Mar 2011

Summer Street Research announces recent closing of financing for IMUC

Summer Street Research Partners is pleased to announce the recent closing of a financing for ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

5 Mar 2011

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Liquidia Technologies today announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative.

5 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

PDI introduces new division for clinical educators to optimize patient care and outcomes

PDI, Inc. today announced the launch of a new division, EngageCE, that will offer expert clinical educators to work with health care providers in the management of chronic diseases in order to optimize patient care and outcomes.

3 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

CTI meets officials of FDA's OND to support pixantrone NDA

Cell Therapeutics, Inc. today announced that it has met with officials of the FDA's Office of New Drugs in Maryland and presented its arguments supporting the Company's belief that the data contained in its New Drug Application 22-481 support the conclusion that pixantrone is effective for its planned use.

3 Mar 2011

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Osiris Therapeutics, Inc., today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack.

3 Mar 2011

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This

2 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

IRX Therapeutics signs research collaboration agreement with world's leading pharma companies

IRX Therapeutics, a developer of immune therapies to make cancer treatments better, announced today it has signed a research collaboration agreement with one of the world's leading research-based pharmaceutical companies.

1 Mar 2011

QLT fourth quarter revenues decrease 7.3% to $10.0 million

QLT Inc. today reported financial results for the fourth quarter ended December 31, 2010 and full year 2010 as well as issued its guidance for 2011. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

1 Mar 2011

Therapeutics News and Research

GTHP provides update on FDA PMA review for LightTouch non-invasive cervical cancer test

IRB approves Guided Therapeutics light-based Barrett's Esophagus detection technology for human trial

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Duchenne Parent Project awards grant to AMT for DMD gene therapy

NCRM, CSCRM to become national force in regenerative medicine

CDI announces publication of footprint-free iPSCs production method in PLoS ONE journal

Summer Street Research announces recent closing of financing for IMUC

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

PDI introduces new division for clinical educators to optimize patient care and outcomes

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

CTI meets officials of FDA's OND to support pixantrone NDA

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

IRX Therapeutics signs research collaboration agreement with world's leading pharma companies

QLT fourth quarter revenues decrease 7.3% to $10.0 million

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News